Vertex Pharmaceuticals Incorporated
VRTX · NASDAQ
Company research
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a Boston-based global biotechnology company founded in 1989 that specializes in the discovery, development, and commercialization of transformative medicines for serious diseases, with a dominant market position in cystic fibrosis (CF) through its portfolio of approved CFTR modulators, including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. Under the leadership of President and CEO Reshma Kewalramani, Vertex has successfully expanded beyond its CF franchise into additional therapeutic areas, with key approved products including CASGEVY, a pioneering gene-editing therapy co-developed with CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta-thalassemia, and JOURNAVX, a novel non-opioid pain medication for moderate-to-severe acute pain in adults. The company maintains a robust and diversified clinical pipeline targeting APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, and myotonic dystrophy type 1, supported by strategic collaborations with partners such as Moderna, CRISPR Therapeutics, and others. With approximately $12 billion in total revenues, elite gross margins above 86%, a fortress balance sheet of over $6.6 billion in cash, and a market capitalization of approximately $123 billion, Vertex stands as one of the most financially robust and scientifically innovative large-cap biotechnology companies in the healthcare sector.
Research reports
Simply Wall St · June 23, 2026Vertex Pharmaceuticals (Nasdaq:VRTX) – Stock Analysis
Simply Wall St’s automated fundamental report views VRTX as trading materially below its estimate of fair value, with earnings forecast to grow about 13% annually, strong balance sheet metrics (zero net debt, high margins) and comparatively low share‑price volatility, while highlighting CF cash‑flow strength and an emerging kidney‑disease franchise as key upside drivers.
Yale School Of Management (Security Analysis Program) · December 24, 2025Vertex Pharmaceuticals Inc. – Yale SOM Security AnalysisYale SOM student analysts recommend VRTX as a BUY with a target price of 473 and roughly 16% implied upside, arguing that Vertex’s dominant cystic fibrosis franchise, expanding gene and cell therapy pipeline (including Casgevy, povetacicept, inaxaplin and diabetes cell therapies) and conservative capital structure support strong, resilient cash flows, while acknowledging execution, pricing, reimbursement and clinical‑trial risks around newer launches and rare‑disease programs.
DBS Bank – US Equity Research · September 19, 2025US EQUITY RESEARCH – Vertex Pharmaceuticals IncDBS’s US Equity Research report rates VRTX BUY with a 12‑month target price of 480, highlighting TRIKAFTA/KAFTRIO‑driven CF revenue growth, a sharp rebound in EBITDA and net income, and management’s reaffirmed guidance as evidence of durable earnings power, while cautioning that heavy reliance on the CF portfolio, setbacks in next‑generation pain program VX‑993 and narrowed JOURNAVX indications create execution risk and make future growth increasingly dependent on successful diversification and regulatory outcomes.